Study Supports Liquid Biopsy to Predict Chemo‑Immunotherapy Benefit in Advanced Lung Cancer

A multi-institutional study co-led by a CU Anschutz investigator shows that liquid biopsy–based genomic profiling can reliably predict benefit from chemo‑immunotherapy in advanced non-small cell lung cancer.